Potential of polylactic-co-glycolic acid (PLGA) for delivery Jembrana disease DNA vaccine Model (pEGFP-C1-tat) |
Unsunnidhal, Lalu
(Department of Reproduction and Obstetrics, Faculty of Veterinary Medicine, University Gadjah Mada)
Wasito, Raden (Department of Pathology, Faculty of Veterinary Medicine, University Gadjah Mada) Setyawan, Erif Maha Nugraha (Department of Reproduction and Obstetrics, Faculty of Veterinary Medicine, University Gadjah Mada) Warsani, Ziana (Research Center of Biotechnology, University Gadjah Mada) Kusumawati, Asmarani (Department of Reproduction and Obstetrics, Faculty of Veterinary Medicine, University Gadjah Mada) |
1 | Laddy DJ, Yan J, Corbitt N, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine. 2007;25(16):2984-2989. DOI |
2 | Porebski BT, Nickson AA, Hoke DE, Hunter MR, Zhu L, McGowan S, et al. Structural and dynamic properties that govern the stability of an engineered fibronectin type III domain. Protein Eng Des Sel. 2015;28(3):67-78. DOI |
3 | Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25(10):1771-1777. DOI |
4 | Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine. 2011;6:2591-2605. |
5 | Palocci C, Valletta A, Chronopoulou L, Donati L, Bramosanti M, Brasili E, et al. Endocytic pathways involved in PLGA nanoparticle uptake by grapevine cells and role of cell wall and membrane in size selection. Plant Cell Rep. 2017;36(12):1917-1928. DOI |
6 | Chen H, Wilcox G, Kertayadnya G, Wood C. Characterization of the Jembrana disease virus tat gene and the cis- and trans-regulatory elements in its long terminal repeats. J Virol. 1999;73(1):658-666. DOI |
7 | Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 1997;11(20):2633-2644. DOI |
8 | Cheng-Mayer C, Shioda T, Levy JA. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J Virol. 1991;65(12):6931-6941. DOI |
9 | Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem. 1996;271(43):27176-27183. DOI |
10 | Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 1997;11(20):2622-2632. DOI |
11 | Chen H, He J, Fong S, Wilcox G, Wood C. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication. J Virol. 2000;74(6):2703-2713. DOI |
12 | Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. 2008;10(5):845-862. DOI |
13 | Unsunnidhal L, Ishak J, Kusumawati A. Expression of gag-CA gene of Jembrana disease virus with cationic liposomes and chitosan nanoparticle delivery systems as DNA vaccine candidates. Trop Life Sci Res. 2019;30(3):15-36. DOI |
14 | Boyoglu S, Vig K, Pillai S, Rangari V, Dennis VA, Khazi F, et al. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine. 2009;5(4):463-472. DOI |
15 | Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol. 1996;6(3):315-324. DOI |
16 | Zhao K, Li GX, Jin YY, Wei HX, Sun QS, Huang TT, et al. Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulated in PLGA microspheres. J Microencapsul. 2010;27(2):178-186. DOI |
17 | Avadi MR, Sadeghi AM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R, et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine (Lond). 2010;6(1):58-63. DOI |
18 | Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522. DOI |
19 | Amir Kalvanagh P, Ebtekara M, Kokhaei P, Soleimanjahi H. Preparation and characterization of PLGA nanoparticles containing plasmid DNA encoding human IFN-lambda-1/IL-29. Iran J Pharm Res. 2019;18(1):156-167. |
20 | Xu Q, Crossley A, Czernuszka J. Preparation and characterization of negatively charged poly(lactic-co-glycolic acid) microspheres. J Pharm Sci. 2009;98(7):2377-2389. DOI |
21 | Porebski BT, Buckle AM. Consensus protein design. Protein Eng Des Sel. 2016;29(7):245-251. DOI |
22 | Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines (Basel). 2013;1(3):225-249. DOI |
23 | Huang T, Song X, Jing J, Zhao K, Shen Y, Zhang X, et al. Chitosan-DNA nanoparticles enhanced the immunogenicity of multivalent DNA vaccination on mice against Trueperella pyogenes infection. J Nanobiotechnology. 2018;16(1):8. DOI |
24 | Obeng-Adjei N, Yan J, Choo D, Weiner D. Immunogenicity of novel consensus-based DNA vaccines against hepatitis B core antigen. J Immunol. 2011;186(1 Suppl):106.1. |
25 | Smith CA, Calabro V, Frankel AD. An RNA-binding chameleon. Mol Cell. 2000;6(5):1067-1076. DOI |
26 | Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577-5591. DOI |
27 | Starodubova S, Kuzmenko YV, Latanova AA, Preobrazhenskaya OV, Karpov VL. Creation of DNA vaccine vector based on codon-optimized gene of rabies virus glycoprotein (G protein) with consensus amino acid sequence. Mol Biol. 2016;50(2):328-331. DOI |
28 | Lucio M, Carvalho A, Lopes I, Goncalves O, Barbara E, Oliveira M. Polymeric versus lipid nanoparticles: comparative study of nanoparticulate systems as indomethacin carriers. J Appl Solut Chem Model. 2015;4(2):95-109. DOI |
29 | Ishak J, Unsunnidhal L, Martien R, Kusumawati A. In vitro evaluation of chitosan-DNA plasmid complex encoding Jembrana disease virus env-tm protein as a vaccine candidate. J Vet Res (Pulawy). 2019;63(1):7-16. DOI |
30 | Zhao K, Li W, Huang T, Luo X, Chen G, Zhang Y, et al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles. PLoS One. 2013;8(12):e82648. DOI |
31 | Mohanraj VJ, Chen Y. Nanoparticles - a review. Trop J Pharm Res. 2006;5(1):561-573. |
32 | Kusumawati A, Wanahari TA, Putri RF, Untari T, Hartati S, Mappakaya BA, et al. Clinical and pathological perspectives of Jembrana disease virus infection: a review. Biosci Biotechnol Res Asia. 2014;11(3):1221-1225. DOI |
33 | Zhao K, Zhang Y, Zhang X, Shi C, Wang X, Wang X, et al. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine. Int J Nanomedicine. 2014;9:4609-4619. DOI |
34 | Agustini NLP, Masa Tenaya IW, Supartika IK. Effication test of Jembrana disease vaccine. Bul Vet. 2009;27(86):1-16. |
35 | Tanaya IWM. Bio-molecular study of Jembrana virus: as basic development of tissue culture vaccine. Bul Vet Udayana. 2016;8(2):187-202. |
36 | Kusumawati A, Wanahari A, Astuti P, Kurniasih , Mappakaya BA, Wuryastuty H. Vaccine against Jembrana disease virus infection: a summary findings. Am J Immunol. 2015;11(3):68-73. DOI |
37 | Suwiti NK. The phenomenon Jembrana disease and bovine immunodeficiency viruses in Bali cattle. Bul Vet Udayana. 2009;1(1):21-25. |
38 | Xu K, Ling ZY, Sun L, Xu Y, Bian C, He Y, et al. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol. 2011;24(1):45-56. DOI |
![]() |